Coverage line comparison

Products liability vs professional liability. Two coverage lines, two distinct triggers.

The two coverages are routinely confused, and the confusion costs operators real money at first claim. Products liability responds to bodily injury or property damage caused by a defective product. Professional liability — errors and omissions — responds to pure economic loss caused by negligent performance of services. They cover different harms, are written on different policy forms, and have different triggering events. The dangerous middle ground is pure economic loss from a failed batch, missed analytical qualification, or scope-creep development work — products policy excludes it, and many life-sciences operators don't carry professional liability to catch it.

Side-by-side

Eight dimensions where the coverages differ.

Dimension

Products Liability

Professional Liability (E&O)

What the policy covers

Bodily injury or property damage caused by a defective product the insured manufactured, sold, or distributed. Includes design defect, manufacturing defect, and failure-to-warn theories.

Economic loss caused by errors, omissions, or negligent performance of professional services. No bodily injury or property damage requirement.

Typical trigger event

A patient or end-user is harmed by the product. Recall events, adverse event reports, and class-action filings are downstream triggers.

A customer suffers financial loss because of how the insured performed services — failed batch caused by formulation error, missed analytical method qualification, delayed regulatory submission, breached protocol.

Policy form

Usually written on an occurrence form (especially for CDMOs and 503Bs). Long-tail claims years after manufacture are common; occurrence form preserves coverage at the date of the occurrence regardless of when the claim is made.

Almost always claims-made. Retroactive date matters — if the retro date is after the engagement started, prior work is uninsured. Tail / Extended Reporting Period (ERP) coverage on termination is structural.

Sub-vertical where it dominates

CDMOs, 503B outsourcing, medical device manufacturers, generic pharma manufacturers, compounding pharmacies. Anyone who makes a physical product that ends up inside or attached to a patient.

CROs, CDMOs with development services, regulatory consulting firms, contract laboratories, bioanalytical services, IP/regulatory consultants. Anyone whose work product is a study, a method, a submission, or advice.

Common gap

Generic insurance brokers place CDMOs on standard manufacturers products liability without recall extension. First recall event (often Class II at minimum) reveals the gap.

CMOs that quietly add development services to scope of work without adding a standalone E&O policy. A failed development batch produces pure economic loss; products policy excludes it.

Limits and pricing

$5M-$10M occurrence is the floor for life-sciences operators; $25M+ for implantable medical devices, biologics, and high-risk drug classes. Premium $0.50-$5.00 per $1,000 revenue depending on product class.

$1M-$5M claims-made is typical floor; $5M-$10M for larger development organizations. Premium materially lower than products — $5,000-$50,000 annual for most mid-market operators.

Coordination with indemnity clauses

Sponsor MSAs and hospital purchase contracts typically require products liability with specific endorsements (AI products/completed ops, primary/non-contributory). Indemnity capped at insurance limits is achievable.

Some MSAs require E&O explicitly; many do not, even when the contracted services include development work. The operator typically carries professional liability for its own protection, not just contract compliance.

When both are needed

Whenever the insured's work product is a physical item that goes into commerce. Products liability is rarely optional for life-sciences manufacturers.

Whenever the insured is paid to apply expertise. CDMOs with development scope, CROs, contract laboratories, regulatory consultants — all need both coverages running in parallel.

The economic-loss doctrine

Why the gap exists in the first place.

The economic-loss doctrine — adopted in some form by every US jurisdiction — bars tort recovery for purely economic damages absent physical injury or property damage. Products liability policies are written against this doctrine: coverage triggers on bodily injury or property damage, which keeps insureds out of tort-only damages disputes.

The gap is straightforward: a CDMO formulates a sponsor's drug product incorrectly. The batch fails stability testing. No patient was harmed; no third-party property was damaged. The sponsor suffers economic loss — wasted API, delayed regulatory submission, missed launch. Products liability does not respond because there is no bodily injury or property damage. Only professional liability picks it up. If the CDMO doesn't carry E&O, the indemnity owed to the sponsor under the MSA becomes uninsured and falls on the CDMO's balance sheet.

The same pattern recurs across the life-sciences supplier ecosystem: CROs that miss a protocol violation flag, contract labs that report incorrect bioanalytical results, regulatory consultants who advise on a submission strategy that gets rejected. All produce economic loss to a sophisticated customer who will pursue contractual remedies. Professional liability is the coverage that responds.

CDMO practice →CRO practice →CDMO vs CMO insurance →Occurrence vs claims-made →Clause glossary →

Free coverage review

Products liability vs professional liability. Two coverage lines, two distinct triggers.

Eight dimensions where the coverages differ.

Why the gap exists in the first place.

A specialist will reach out by the end of the day.

Request the review